S&P Futures
4,137.50+4.75(+0.11%)Dow Futures
33,581.00+11.00(+0.03%)Nasdaq Futures
14,022.25+46.50(+0.33%)
Lantheus Holdings, Inc. (LNTH)
Chart Events
Performance Outlook
| Previous Close | 21.01 |
| Open | 21.01 |
| Bid | 20.00 x 1100 |
| Ask | 21.99 x 800 |
| Day's Range | 20.77 - 21.20 |
| 52 Week Range | 10.52 - 21.99 |
| Volume | 516,726 |
| Avg. Volume | 583,246 |
| Market Cap | 1.41B |
| Beta (5Y Monthly) | 1.21 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
Lantheus Expands R&D Leadership Team with Key New Hires
Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find, Fight and Follow serious medical conditions, today announced the hiring of Dr. Bela Denes and Dr. Iryna Teslenko. Both report directly to Lantheus’ Chief Medical Officer, Istvan Molnar, MD.
- Business Wire
Lantheus Announces Retirement of Michael P. Duffy, Senior Vice President and General Counsel
Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find, Fight and Follow serious medical conditions, today announced that Michael P. Duffy, Senior Vice President, Law and Public Policy and General Counsel will retire from Lantheus on June 4, 2021 after more than 13 years with Lantheus. Mr. Duffy will be retained in an advisory capacity. His responsibilities will be assumed by Daniel Niedzwiecki, who has been with the Company since 2013 and will report directly to Mary Anne Heino, President and CEO.
- Business Wire
Lantheus Acquires Rights to Innovative Imaging Biomarker Targeting Fibroblast Activation Protein (FAP) from Noria
Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find, Fight and Follow serious medical conditions, announced today it has acquired the exclusive, worldwide rights to develop, manufacture and commercialize NTI-1309, an innovative PET oncology imaging agent from Noria Therapeutics, Inc.
